Absence of Black Box Warning For Bristol Myers' Schizophrenia Treatment Could Enhance Alzheimer's Psychosis Potential
Cobenfy (xanomeline and trospium chloride, KarXT), an oral medication for schizophrenia in adults. BMO Capital analyst notes ...
New schizophrenia drug ‘could change the lives of millions of people’
A groundbreaking new drug to treat schizophrenia called Cobenfy, owned by pharmaceutical firm Bristol Myers Squibb, has been ...
Pharmaceutical Technology39m
FDA greenlights Regeneron’s Dupixent for the treatment of COPD
With an approval based on two pivotal Phase III studies, Dupixent is now the first-ever biologic indicated for treating COPD.
MM&M45m
Bristol Myers Squibb wins FDA approval for first new schizophrenia drug in 30 years
Cobenfy targets cholinergic receptors instead of the dopamine receptors long addressed in current schizophrenia drugs — a new treatment approach to the disease.